A strong oulook in IT healthcare is failing to lift this imaging platform provider today
The post The Mach7 (ASX:M7T) share price slips despite strong IT healthcare outlook appeared first on The Motley Fool Australia. –
At the time of writing, the Mach7 share price is trading at $1.03, down 0.5% today and 13.7% year-to-date.
Mach7 develops image management and viewing solutions for healthcare providers. Its solutions consolidate imaging data into a single platform, providing clinicians with fast access to diagnostic images with rich features on any browser or device.
Mach7 share price lower despite solid outlook
The investor presentation included outlook commentary for the imaging market and Mach7 business.
Mach7 observed that the “uncertainty and volatility brought on by the pandemic, hugely disruptive for the imaging IT market, is receding”. Instead, the new era of remote working has put pressure on imaging IT to remove barriers to streamline remote diagnosis for radiologists.
The company believes the “heightened focus on IT healthcare spend” could drive more opportunities for the enterprise imaging solutions market. Mach7 points out that the return of in-person trade shows will be a tailwind to accelerate purchasing decisions and contract wins.
Mach7 revealed that it had received purchase orders from Trinity Healthcare and Adventist Health as both healthcare providers implement their Mach7 solutions across FY22.
Looking ahead, the company believes its pipeline conversion could accelerate as customers begin to “normalise their staffing levels and assign budgets”.
The Mach7 share price so far in 2021
The Mach7 share price started the year strong, climbing ~30% to highs of $1.59. However, its sharp February selloff broadly coincided with the weakness across tech and growth-related sectors.
However, its record third-quarter results on 12 April demonstrated a strong bounce back in financial performance. The Mach7 share price jumped 9.2% from $1.26 to $1.375 on the day.
Unfortunately, the bullishness from the quarterly report was short lived, with its shares sliding below $1.26 just a few weeks later.